P. Kent Hawryluk is CEO & President at MBX Biosciences, Inc. (MBX). They have made 6 open-market trades across 2 companies since 2016, most recently 2026-05-06.
CIK 0001673991
5 open-market purchases totalling $2.1M since 2016, against 1 sale. Across 5 scored buys the stock is up 40.8% at ninety days, and 39.4 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| MBX | 727,667 | $36.1M |
| GEMP | 81,889 | $614K |
| Total | $36.8M |
Shares reported on the most recent Form 4, priced at the 2026-05-08 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 80% | 60% |
| Avg Move | +11.1% | +22.2% | +40.8% |
| Alpha | +11.8% | +23.6% | +39.4% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MBX | SELL | 2026-05-06 | 2026-05-08 | $29.54 | $18K | -23.4% | -29.3% | +63.4% |
| MBX | BUY | 2026-03-13 | 2026-03-16 | $28.41 | $526K | -3.7% | +12.2% | +33.1% |
| MBX | BUY | 2025-10-20 | 2025-10-21 | $13.64 | $273K | +39.7% | +71.9% | +174.4% |
| MBX | BUY | 2025-02-04 | 2025-02-05 | $10.69 | $535K | -15.5% | -23.3% | -16.1% |
| GEMP | BUY | 2017-03-10 | 2017-03-14 | $9.47 | $474K | +30.4% | +23.9% | +16.0% |
| GEMP | BUY | 2016-08-10 | 2016-08-12 | $10.00 | $250K | +4.7% | +26.3% | -3.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.